Basel, February 24, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, announces the launch of Pyzchiva®* (ustekinumab-ttwe) in the US. From today, the ...

But there are non-infectious causes of infertility to consider as well.  In this episode, Dr. Fauna Smith, Assistant ...

In just a few short weeks, the Trump administration has brought drastic changes to the Centers for Disease Control and ...

INCHEON, Korea I February 24, 2025 I Samsung Bioepis Co., Ltd. today announced that PYZCHIVA® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), is ...

PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) ("PetVivo") an emerging biomedical device company focused on the ...

Bird flu continues to spread to farm animals, raising concerns about whether it's safe to drink milk or eat beef, eggs, and ...

BRIDGEWATER, NJ, USA and BENGALURU, India I4, 2025 I Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars ...

Implantable cardiac devices play a significant role in decreasing the morbidity and mortality in patients with cardiovascular disease. Tissue-device interactions leading to systemic ...